Press Clippings

Measuring the effectiveness of immunotherapy treatment for hay fever allergy

World Allergy Organization

AAN: Statin Therapy May Slow MS Progression

MedPage Today
TORONTO -- The risk of developing new brain lesions was reduced by about 50% if patients with early forms of multiple sclerosis were taking atorvastatin (Lipitor), researchers said here at the annual meeting of the American Academy of Neurology.

The results are from an 18-month study designed to see whether statin therapy could slow the progression of multiple sclerosis.

Revealing the mechanisms of tolerance

Clinical & Translational Science

Inducing remission in ANCApositive vasculitis: time to RAVE?

Nature Reviews Rheumatology
Standard therapy for vasculitis associated with antineutrophil
cytoplasmic antibodies can achieve high rates of remission, but with the
risk of serious toxic effects. the results of a placebo-controlled trial in
patients with severe disease suggest that an effective alternative could
be on the horizon.

Can Peanut Allergies Be Cured by ... Eating Peanuts?

In 2008, Gideon Lack of King's College London published a startling study comparing the rate of peanut allergies in children in London with that of children in Tel Aviv. The study of 10,000 Jewish children, which appeared in the Journal of Allergy and Clinical Immunology, found that kids in the U.K. were almost 10 times as likely to have a peanut allergy as their peers in Israel, says Lack.

Rebooting the body

Popular Science

Researchers Discover Potential Diabetes Cure

Harvard Crimson

Fighting Peanut Allergies With Peanuts

ABC News

New Research and New Approaches Offer Hope to Families Coping With Food Allergies


Three-year-old Peyton Youse of Charlotte, N.C., is severely allergic to peanuts.

But now doctors are fighting back -- with peanuts.

Rho brings multi-million dollar federal contract to RTP

Rho, Inc., a scientific/medical contract research organization that serves the biotechnology and pharmaceutical industries and the National Institutes of Health (NIH), has been awarded a six-year, $38.9 million contract through the National Institute of Allergy and Infectious Diseases (NIAID) to provide biostatistical, data management, and safety services to the Immune Tolerance Network (ITN).

86 Years After Insulin, Type I Diabetes Drugs Promise More

BioWorld Today

Original article at BioWorld Today

By Karen Pihl-Carey




Senior Staff Writer, BioWorld Today

In the early part of the 20th century, before the Depression and World War II, dozens of children lay comatose in hospital wards where hopeless families gathered awaiting their inevitable deaths.

A successful mixture: Transplanting immune-system stem cells along with kidneys stops rejection

The Economist

In Diabetic Mice, Antibody Therapy Activates Disease-Controlling, Regulatory T Cells

JDRF Frontline

Breakthrough spares kidney transplant patients

LOS ANGELES -- In what's being called a major advance in organ transplants, doctors say they have developed a technique that could free many patients from having to take anti-rejection drugs for the rest of their lives.

The treatment involved weakening the patient's immune system, then giving the recipient bone marrow from the person who donated the organ. In one experiment, four of five kidney recipients were off immune-suppressing medicines up to five years later.

Doctors report transplant breakthrough

Associated Press
by Alicia Chang, 24 January 2008

LOS ANGELES (AP) - In what's being called a major advance in organ transplants, doctors say they have developed a technique that could free many patients from having to take anti-rejection drugs for the rest of their lives.

Study: Transplant Patients Stop Rejection Drugs

All Things Considered, January 23, 2008 · Organ transplants have saved thousands of lives over the past 50 years. But to prevent rejection of transplanted organs, patients have to take toxic drugs for the rest of their lives.

Now, several new studies show that it's possible for some transplant patients to avoid these drugs and their side effects. The studies appear in this week's New England Journal of Medicine.

One of the first transplant patients who volunteered to stop taking anti-rejection drugs was Jennifer Serle.